A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

Exclusion Criteria

• •1. Difference between arms greater than 20 mmHg for mean sitSBP or 10mmHg for mean sitDBP at Visit 1
• •2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1
• •3. Orthostatic hypotension with symptoms within 3 months prior to visit 1
• •4. Secondary hypertension patient or suspected to be
• •5. Uncontrolled type II diabetes mellitus (HbA1c \> 9%) or type I diabetes mellitus
• •6. Severe heart disease or severe neurovascular disease
• •7. Moderate or malignant retinopathy
• •8. Severe renal diseases (eGFR\<30mL/min/1.73m2)
• •9. Severe or active hepatopathy (AST or ALT ≥ 2 times of normal range)
• •10. Hypokalemia or Hyperkalemia (K\<3.5mmol/L or K ≥ 5.5mmol/L)
• •11. Hyponatremia or Hypernatremia (Na\<135mmol/L or Na ≥ 155mmol/L)
• •12. History of malignancy tumor
• •13. History of alcohol or drug abuse
• •14. Positive to pregnancy test, nursing mother, intention on pregnancy
• •15. Considered by investigator as not appropriate to participate in the clinical study with other reason